Safety of Mexidol^® (ethylmethylhydroxypyridine succinate) in adult patients of different age groups

Author:
E.A. USHKALOVA¹, S.K. ZYRYANOV^1,2, O.I. BUTRANOVA¹

¹RUDN University, Moscow; ²City Clinical Hospital No. 24, Department of Healthcare of Moscow, Moscow

Summary:
To reduce the risk of developing adverse events (AEs) and increase the adherence of elderly patients to treatment, it is recommended to limit maximally the total number of prescribed drugs (DR), using one drug for the treatment of two or more pathologies if possible. The drugs that meet the criteria for use in elderly patients and / or patients with comorbidity include the original Russian drug Mexidol^® (ethylmethylhydroxypyridine succinate), which has a multimodal mechanism of action and has multiple pharmacological effects. In order to study the safety of Mexidol in comparison with placebo in different age groups of patients with chronic cerebral ischemia, a post hoc analysis of the international multicenter, randomized, double-blind, placebo-controlled MEMO study with an adaptive design was carried out, which assessed the efficacy and safety of sequential therapy with Mexidol^®, a solution for intravenous and intramuscular injection, 50 mg/ml (NPK PHARMASOFT, Russia) and Mexidol^® FORTE 250 film-coated tablets, 250 mg (NPK PHARMASOFT, Russia) in patients with chronic cerebral ischemia. The study involved 318 patients aged from 40 to 90 years. Comparable safety and tolerability of Mexidol was demonstrated in middle-aged and elderly people with chronic cerebral ischemia, including patients over 75 years of age. Keywords: adult patients of different age groups; elderly; MEMO research; Mexidol^®; Mexidol^® FORTE 250; ethylmethylhydroxypyridine succinate; safety.